Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages 1-4

  Jilg, Cordula A ^a   Leifert, Anja ^a   Schnell, Daniel ^a   Kirste, Simon ^a   Volegova Neher, Natalia ^a   Schlager, Daniel ^a   Wieser, Gesche ^a   Henne, Karl ^a   Schultze Seemann, Wolfgang ^a   Grosu, Anca L ^a   Rischke, Hans C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adjuvant radiotherapy; Choline PET; Lymph node metastases; PET CT; Prostate cancer relapse; Salvage lymphadenectomy; Toxicity of radiotherapy

Indexed keywords

CHOLINE C 11; FLUORETHYLCHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CARBON; CHOLINE; FLUORINE;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIARRHEA; DISEASE SEVERITY; ERYTHEMA; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; LYMPHOCELE; MALE; PELVIC DISEASE; PHYSICAL EXAMINATION; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION INJURY; RETROPERITONEAL DISEASE; SALVAGE THERAPY; URINE INCONTINENCE; ADJUVANT RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS; SCINTISCANNING; TUMOR RECURRENCE;

AGED; CARBON RADIOISOTOPES; CHOLINE; FLUORINE RADIOISOTOPES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84906832868     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-178     Document Type: Article

References (29)

1. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997, 349(9056):906-910. 10.1016/S0140-6736(96)09380-4, 9093251.
2. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003, 169(2):517-523. 10.1016/S0022-5347(05)63946-8, 12544300.
3. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, Hricak H. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004, 231(2):379-385. 10.1148/radiol.2312030011, 15064390.
4. Bottke D, Bartkowiak D, Schrader M, Wiegel T. Radiotherapy after radical prostatectomy: immediate or early delayed?. Strahlenther Onkol 2012, 188(12):1096-1101. 10.1007/s00066-012-0234-9, 23128897.
5. Rischke HC, Knippen S, Kirste S, Grosu AL. Treatment of recurrent prostate cancer following radical prostatectomy: the radiation-oncologists point of view. Q J Nucl Med Mol Imaging 2012, 56(5):409-420.
6. Shelan M, Abo-Madyan Y, Welzel G, Bolenz C, Kosakowski J, Behnam N, Wenz F, Lohr F. Dose-escalated salvage radiotherapy after radical prostatectomy in high risk prostate cancer patients without hormone therapy: outcome, prognostic factors and late toxicity. Radiat Oncol 2013, 8:276. 10.1186/1748-717X-8-276, 24279376.
7. Rischke HC, Schafer AO, Nestle U, Volegova-Neher N, Henne K, Benz MR, Schultze-Seemann W, Langer M, Grosu AL. Detection of local recurrent prostate cancer after radical prostatectomy in terms of salvage radiotherapy using dynamic contrast enhanced-MRI without endorectal coil. Radiat Oncol 2012, 7:185. 10.1186/1748-717X-7-185, 3560084, 23114282.
8. Jilg CA, Schultze-Seemann W, Drendel V, Vach W, Wieser G, Krauss T, Jandausch A, Holz S, Henne K, Reske SN, Grosu AL, Weber WA, Rischke HC. Detection of lymph node metastasis in patients with nodal prostate cancer relapse using F/C-choline positron emission tomography/computerized tomography: influence of size of nodal tumor infiltration and accuracy related to lymph node regions. J Urol 2014, doi:10.1016/j.juro.2013.12.054. [Epub ahead of print].
9. Higano C. Androgen-deprivation therapy for prostate cancer. Clin Prostate Cancer 2003, 2(1):22-23. 10.1016/S1540-0352(11)70015-4, 15046679.
10. Benson RC. Total androgen blockade: the United States experience. Eur Urol 1993, 24(Suppl 2):72-76.
11. Crehange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev 2012, 38(8):956-967. 10.1016/j.ctrv.2012.05.005, 3739983, 22703831.
12. Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer: a new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009, 55(2):261-270. 10.1016/j.eururo.2008.09.043, 18838212.
13. Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, Drendel V, Schwardt M, Jandausch A, Schultze-Seemann W. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012, 188(6):2190-2197. 10.1016/j.juro.2012.08.041, 23083862.
14. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 2011, 60(5):935-943. 10.1016/j.eururo.2011.07.060, 21840116.
15. Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, Zerini D, Gherardi F, Ascione C, Bossi-Zanetti I, Mauro R, Bregantin A, Bianchi LC, De Cobelli O, Orecchia R. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82(2):889-897. 10.1016/j.ijrobp.2010.11.031, 21277113.
16. De Bari B, Alongi F, Buglione M, Campostrini F, Briganti A, Berardi G, Petralia G, Bellomi M, Chiti A, Fodor A, Suardi N, Cozzarini C, Nadia DM, Scorsetti M, Orecchia R, Montorsi F, Bertoni F, Margrini SM, Jereczek-Fossa BA. Salvage therapy of small volume prostate cancer nodal failures: a review of the literature. Crit Rev Oncol Hematol 2014, 90(1):24-35. 10.1016/j.critrevonc.2013.11.003, 24315428.
17. Beesley V, Janda M, Eakin E, Obermair A, Battistutta D. Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. Cancer 2007, 109(12):2607-2614. 10.1002/cncr.22684, 17474128.
18. Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Lymphedema and bladder-emptying difficulties after radical hysterectomy for early cervical cancer and among population controls. Int J Gynecol Cancer 2006, 16(3):1130-1139. 10.1111/j.1525-1438.2006.00601.x, 16803496.
19. Ryan M, Stainton MC, Slaytor EK, Jaconelli C, Watts S, Mackenzie P. Aetiology and prevalence of lower limb lymphoedema following treatment for gynaecological cancer. Aust N Z J Obstet Gynaecol 2003, 43(2):148-151. 10.1046/j.0004-8666.2003.00040.x, 14712972.
20. Lawton CA, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007, 69(3):646-655. 10.1016/j.ijrobp.2007.04.003, 2917177, 17531401.
21. Fiorino C, Alongi F, Perna L, Broggi S, Cattaneo GM, Cozzarini C, Di Muzio N, Fazio F, Calandrino R. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 2009, 75(1):29-35. 10.1016/j.ijrobp.2008.10.086, 19467803.
22. National cancer institute common terminology criteria for adverse events v4.0 2009, NCI, NIH, DHHS, NIH publication # 09-7473. Link: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf.
23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85(5):365-376. 10.1093/jnci/85.5.365, 8433390.
24. van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, D'Haese S, Aaronson NK. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008, 44(16):2418-2424. 10.1016/j.ejca.2008.07.030, 18774706.
25. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, . Group obotEQoL The EORTC QLQ-C30 scoring manual (3rd edition) 2001, Brussels: Published by: European Organisation for Research and Treatment of Cancer, Group obotEQoL.
26. Rasmusson E, Gunnlaugsson A, Blom R, Bjork-Eriksson T, Nilsson P, Ahlgen G, Jonsson C, Johansson K, Kjellen E. Low rate of lymphedema after extended pelvic lymphadenectomy followed by pelvic irradiation of node-positive prostate cancer. Radiat Oncol 2013, 8:271. 10.1186/1748-717X-8-271, 3842657, 24252686.
27. Muller AC, Lutjens J, Alber M, Eckert F, Bamberg M, Schilling D, Belka C, Ganswindt U. Toxicity and outcome of pelvic IMRT for node-positive prostate cancer. Strahlenther Onkol 2012, 188(11):982-989. 10.1007/s00066-012-0169-1, 23053142.
28. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997, 350(9077):535-540. 10.1016/S0140-6736(97)02250-2, 9284774.
29. Adams E, Boulton MG, Horne A, Rose PW, Durrant L, Collingwood M, Oskrochi R, Davidson SE, Watson EK. The effects of pelvic radiotherapy on cancer survivors: symptom profile, psychological morbidity and quality of life. Clin Oncol (R Coll Radiol) 2014, 26(1):10-17. 10.1016/j.clon.2013.08.003, 23992740.